Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Non-Current Deffered Revenue: 2015-2023

Historic Non-Current Deffered Revenue for Cartesian Therapeutics (RNAC) over the last 8 years, with Dec 2023 value amounting to $3.5 million.

  • Cartesian Therapeutics' Non-Current Deffered Revenue was N/A to $3.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was $3.5 million, marking a year-over-year change of. This contributed to the annual value of $3.5 million for FY2023, which is N/A change from last year.
  • According to the latest figures from Q4 2023, Cartesian Therapeutics' Non-Current Deffered Revenue is $3.5 million, which was down 11.13% from $4.0 million recorded in Q3 2023.
  • In the past 5 years, Cartesian Therapeutics' Non-Current Deffered Revenue registered a high of $51.5 million during Q3 2020, and its lowest value of $3.5 million during Q4 2023.
  • Its 3-year average for Non-Current Deffered Revenue is $11.8 million, with a median of $7.1 million in 2022.
  • Per our database at Business Quant, Cartesian Therapeutics' Non-Current Deffered Revenue skyrocketed by 10,610.08% in 2019 and then plummeted by 72.90% in 2022.
  • Cartesian Therapeutics' Non-Current Deffered Revenue (Quarterly) stood at $14.7 million in 2019, then spiked by 163.94% to $38.7 million in 2020, then crashed by 70.53% to $11.4 million in 2021, then slumped by 72.90% to $5.4 million in 2022, then declined by 26.77% to $3.5 million in 2023.
  • Its Non-Current Deffered Revenue stands at $3.5 million for Q4 2023, versus $4.0 million for Q3 2023 and $4.9 million for Q2 2023.